A Randomized, Placebo-controlled, Double-blinded, Crossover Trial of Pioglitazone for Severe Asthma

The PPAR-γ agonist, pioglitazone, was associated with significant side effects and did not improve the primary outcome measure of the Juniper Asthma Quality of Life Questionnaire (AQLQ) score in severe asthmatics. We conclude that no further studies should be performed with pioglitazone for severe a...

詳細記述

保存先:
書誌詳細
出版年:J Allergy Clin Immunol
主要な著者: Kaler, Maryann, Barochia, Amisha V., Weir, Nargues A., Cuento, Rosemarie A., Stylianou, Mario, Roth, Mark J., Filie, Armando C., Vaughey, Ellen C., Nathan, Steven D., Levine, Stewart J.
フォーマット: Artigo
言語:Inglês
出版事項: 2017
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5723231/
https://ncbi.nlm.nih.gov/pubmed/28625806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaci.2017.05.033
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料